Hereditary multiple exostosis (EXT) is an autosomal dominant condition mainly
INTRODUCTION
Multiple exostoses syndrome (EXT) is a heritable skeletal disorder of enchondral bone formation. The cardinal clinical symptom is the presence of multiple exostoses, most typically located in the metaphyseal bone cortex adjacent to the epiphyseal plate of long bones such as femur, tibia, humerus, ulna and radius. Exostoses are cartilage-capped osseous projections emanating from the bones which are rarely present at birth, but gradually develop and increase in size in the first decade of life (1) (2) (3) (4) (5) (6) (7) (8) (9) . Pathologic examination of these exostoses revealed that they consist of benign enchondromata (2, 4) . Apart from the typical exostoses, patients with EXT have a generalized defective (re)modeling of bone, especially of the metaphyses of long bones. This leads to abnormal skeletal growth resulting in short stature, and abnormal bone formation, which is responsible for clubshaped metaphyseal widening, cortical irregularities and in some cases gross deformities, especially of the forearm (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) .
Sarcomatous degeneration of one of the enchondromata to chondrosarcoma or osteosarcoma occurs in ∼2% of cases (7) (8) (9) .
Multiple exostoses has an estimated prevalence of 1/50 000 (7). It can occur as an isolated condition with autosomal dominant inheritance (EXT), or as part of microdeletion syndromes. EXT is an autosomal dominant disorder with incomplete penetrance and a skewed sex-ratio with more affected males than females. It is genetically heterogeneous with at least three loci. The EXT1 gene on chromosome 8q24.1 has recently been identified (12) , whereas two other genes, EXT2 and EXT3, have been mapped to chromosomes 11p11-p12 (13, 14) and 19p (15) respectively. As most EXT families show linkage to EXT1 or EXT2, the EXT3 locus is probably a minor locus (16) . Although the EXT1 gene has been cloned, no homology to any other known gene was found, thereby hampering the elucidation of its function (12) . However, as some chondrosarcoma and osteosarcoma show loss-of-heterozygosity (LOH) of the EXT regions on chromosomes 8 and 11, the EXT *To whom correspondence should be addressed genes might be tumor-suppressor genes (17) (18) (19) . The EXT1 and EXT2 genes are also involved in two distinct microdeletion syndromes, both characterized by the presence of multiple exostoses. One copy of the EXT1 gene is constitutionally deleted in the Langer-Giedion syndrome, which is a contiguous gene syndrome caused by deletion of both the EXT1 and the TRPS I gene (12, (20) (21) (22) . Also EXT2 has been implicated in a microdeletion syndrome, . Patients with DE-FECT 11 syndrome show interstitial Deletions of the proximal part of chromosome 11p encompassing the EXT2 candidate region, Enlarged parietal Foramina (FPP), multiple Exostoses, Craniofacial dysostosis and mental reTardation. It is possible that the DEFECT 11 syndrome is a contiguous gene syndrome resulting from the deletion of different genes, including EXT2 and FPP. This hypothesis is supported by the fact that also FPP, in analogy to EXT2, can occur as an isolated condition with an autosomal dominant mode of inheritance (26, 27) .
In this study we constructed a contig of YAC and P1 clones of the EXT2 candidate region. One of the transcribed sequences isolated from this region showed homology to the EXT1 gene and was found to harbour different inactivating mutations in patients with EXT2, thereby indicating that this gene is the EXT2 disease gene.
RESULTS

Refinement of the EXT2 candidate region
Linkage studies in large multiplex EXT2 families and analysis of key recombinational events have previously defined a minimal cosegregating region or genetic candidate region (14) between the anonymous microsatellite markers D11S1355 (telomeric side) and D11S1361/D11S554 (centromeric side). On the Géné-thon map (28) this region is ∼3 cM. Markers D11S578, D11S1393 and D11S2095 are not integrated on this map, but were localized between D11S1355 and D11S1361 by PCR analysis on our YAC/P1 panel (see below), which is in agreement with the radiation hybrid map (29) . Analysis of key recombinants in our EXT2 families revealed no crossover between EXT2 and these markers. One EXT2 family with a small molecular deletion only detected by D11S903 has been reported (16, 18) , but a detailed delineation of this deletion has not yet been reported. Deletions of the EXT2 region are also present in patients with Defect 11 syndrome (23) (24) (25) . In nearly all cases these deletions comprise the complete EXT2 candidate region as delineated by linkage analysis (23) (24) (25) . However, molecular analysis of a patient with characteristics of DEFECT 11 syndrome, including multiple exostoses, foramina parietale permagna (FPP), mental retardation and micropenis (30) , showed a maternal deletion with a distal breakpoint between D11S914 and D11S915, and a proximal deletion breakpoint between D11S2095 and D11S935. As D11S2095 and markers centromeric of D11S2095 are not deleted in this patient with multiple exostoses, the candidate EXT2 region can be refined to the interval between D11S1355 and D11S2095 ( Fig. 1) .
Construction of a yeast artificial chromosome contig
To construct a yeast artificial chromosome (YAC) contig spanning the EXT2 candidate region, we first searched in the CEPH YAC database for YACs that were positive for microsatellite markers located in the EXT2 candidate region. For D11S1355, the distal boundary of the EXT2 candidate region, several YACs were present in the database (Table 1) . Only two CEPH YACs (798A12 and 923B11) could be identified for D11S903, a marker located within the candidate interval. D11S2095, the flanking marker on proximal side was not present in the CEPH YAC database (Fig. 1) . To extend this set of YACs we screened the CEPH, ICRF libraries and a chromosome 11-specific YAC library (31) with the markers mentioned above, and additionally also with D11S578 and D11S1393. The presence of these markers on the YACs was analyzed by PCR and hybridization. This resulted in the construction of a YAC contig bridging the complete EXT2 candidate region between D11S1355 and D11S2095 (Table 1 and Fig. 1 ). The EXT2 region is encompassed by two overlapping YACs with a size of 300 kb (YAC 650E6) and 400 kb (YAC 1B10) respectively. Therefore, the EXT2 candidate region is <700 kb assuming that no deletions in those two YACs are present. YAC 923B11 has a large size (1690 kb), but this might be due to its chimeric nature as it contains genomic fragments from chromosomes 2, 6 and 11. However, since all microsatellite markers within the EXT2 candidate region with the exception of D11S1355, were found to be present in YAC 923B11, this YAC was used for the screening of a P1 library.
Isolation and mapping of P1 clones
Using DNA from the YAC 923B11 as a probe, 20 P1 clones were selected from gridded P1 membranes (ICRF). As it was not evident that these P1 clones are derived from chromosome 11p in view of the chimeric character of this YAC, we performed FISH analysis on metaphase chromosomes. P1 clones were mapped relative to cosmid ICRFcE07123, which is positive for D11S1355 and cosmid cCI11-388, which is positive for D11S1361. Out of the 20 clones 13 could be mapped back to the EXT2 region between D11S1355 and D11S1361. The relative ordering of these various P1 clones was obtained on interphase nuclei and by fiber FISH. PCR analysis of these 13 clones with D11S578, D11S1393, D11S903 and D11S2095 revealed six positive clones. Two clones were positive for D11S578 (M1637, H1623), two for D11S1393 (O1366, P14117), one for D11S903 (A1151) and one for D11S2095 (D0694).
Isolation of expressed sequences from the candidate region
cDNA selection experiments were performed to isolate cDNA clones from the EXT2 candidate region. Fragmented cDNA with a size of ∼500 base pair (bp) obtained from human liver tissue was enriched for fragments from the EXT2 candidate region by hybridization in different rounds to P1 DNA. P1 clones used in this experiment were M1637, H1623, O1366, P14117, A1151 and D0694, all positive for one of the markers from the candidate region. After subcloning of the eluted fragments, clones were hybridized to these P1s to confirm their localization within the candidate region.
Isolation of EXT2 cDNAs
Hybridization of one of the cDNA selection clones, cDNAS, to the Soares' foetal brain cDNA library (34) resulted in a single positive cDNA clone, 288f10 (Fig. 1) . The 1813 bp sequence of this clone showed an open reading frame (ORF) coding for 224 amino acids. Since clone 288f10 showed homology at the protein Figure 1 . Physical map of the EXT2 candidate region, and experimental strategy of the positional cloning of the EXT2 gene.The genetic map with the candidate interval between D11S1355 and D11S2095 is indicated by a heavy bar. The map is not to scale. YAC, P1, cosmid and cDNA clones are indicated. YAC 923B11 was used to isolate the P1 clones. Relative positions of the various P1 clones were obtained by fiber FISH. cDNA 288f10 was isolated from the Soares' cDNA library by hybridization with cDNAS, which was isolated by cDNA selection. Homology searches with the sequence of 288f10 revealed homology with the EXT1 gene. Additionally, several ESTs with complete homology were found in the TIGR database. One of these ESTs (yf69b06.s1) is derived from a TIGR cDNA clone yf69bo6 whose 5′ end (EST yf69b06.r1) also shows homology to the EXT1 cDNA. RT-PCR experiments using both ESTs were performed to amplify a PCR product representing cDNA yf69bo6. The 5′ end of the EXT2 cDNA sequence was obtained by 5′ RACE experiments using primers L2 and C2. level with the EXT1 gene, it might represent part of the EXT2 cDNA, and was therefore pursued.
A search in databank dbEst using the NBLAST program (35) with the 1813 bp sequence of cDNA 288f10 identified several expressed sequence tags (ESTs), assembled in The Institute for Genome Research (TIGR) tentative human consensus (THC) sequence THC122727. Sixteen ESTs are located within this THC contig, representing a total sequence of 1267 bp. This contig is linked by cDNA clone yf69b06 (R14096) to THC79320 since EST yf69b06.s1 is within contig THC122727, while yf69b06.r1 is within THC79320 (Fig. 1) . The intervening 513 bp sequence between these two contigs was amplified by RT-PCR on lymphoblastoid mRNA and sequenced. Sequential 5′ rapid amplification of cDNA ends (RACE) experiments using primers L2 and C2 were performed to obtain the 5′ end of the EXT2 gene ( Fig. 1) . Sequencing of the resulting RACE clones revealed that the three largest clones showed the same 5′ end, suggesting that this represents the 5′ end of the EXT2 cDNA. Therefore, the first in-frame ATG found in the cDNA, is most likely the initiation codon, although its surrounding sequence has limited homology to the Kozak consensus sequence (Fig. 2) . Comparison with the position of the start codon in human (12) and mouse (X96639) EXT1 further confirms that the first in-frame ATG of EXT2 is indeed the start codon (Fig. 3B ). The 5′ untranslated region (UTR) of EXT2 is much shorter (26 bp) than the exceptionally long 5′ UTR (652 bp) of EXT1 (Fig. 3A) . The 3′ UTR of EXT2 contains a consensus polyadenylation signal ATTAAA located and N 637 are bold and underlined. The polyadenylation signal ATTAAA is underlined. The sequence is followed by a poly(A) tail at the 3′ end. The sequence has been submitted to GenBank (accession no. U64511).
27 bp upstream of the poly(A) tail (Fig. 2) . Its total length is 1140 bp which is much longer than that of EXT1 (276 bp). A database search revealed one EST clone NIB920 (T17444) containing 152 bp extra at the 3′ end. However, so far we have not been able to confirm this and therefore this sequence was not included.
The compiled cDNA sequence of EXT2 is 3320 bp, which is in good agreement with the length of the mRNA on Northern blots. Hybridization of the yf69bo6 cDNA clone to a commercially available Northern blot (Clontech) containing eight different human tissues, identified a major transcript of ∼3.2 kb. A minor transcript of 3.5 kb is also present in all tissues, the ratio between both signals being fairly constant (Fig. 4) . This suggests that both transcripts are derived from the EXT2 gene and might be alternative splicing products. Another possibility is that the minor transcript corresponds to an EXT2 homologue elsewhere in the genome. Based upon the size of the signal, it could be the 3.4 kb EXT1 transcript (12) . However, the homology between EXT1 and EXT2 is probably too low to result in a signal on Northern blots. Furthermore, the expression pattern of EXT1 (high expression in liver and low expression in heart) is clearly different from that of EXT2, which shows the highest expression in heart, placenta and pancreas, and low expression in brain and kidney. Lung, liver and skeletal muscle show intermediate EXT2 expression (Fig. 4) . It is therefore unlikely that the minor Northern blot signal represents EXT1.
Hybridization of the EXT2 cDNA to P1 clones from the EXT2 candidate region (Fig. 1) indicates that parts of EXT2 are present in D0494, A1151and D0694, which suggests that the EXT2 gene is a large gene. This is also shown by fiber FISH experiments (Fig. 5) . However, this remains to be confirmed by determination of the genomic structure of the EXT2 gene. The open reading frame (ORF) of EXT2 contains 2154 bp and encodes 718 amino acids (Figs 2 and 3) . The predicted molecular weight is 82.3 kDa. Alignment of EXT1 and EXT2 at the amino acid level revealed an overall sequence identity of 30.9%. In the 5′ region of EXT2 only a low degree of homology is found (18% for amino acids 1-302). The 3′ region shows a higher degree of homology than Figure 5 . Localization of human EXT2 cDNA yf69bo6 between D11S578 and D11S1361. Three-color fiber FISH was performed using a digoxigenin-labelled P1 clone M1637 positive for D11S578 (red), a biotin-labeled cDNA of EXT2 (green) and a biotin/digoxigenin-labelled cosmid clone cC11-388 positive for D11S1361 (red + green or orange).
the 5′ region (48% between amino acids 520 and 718). EXT2 has two possible N-glycosylation sites, multiple phosphorylation sites and one cell attachment sequence RGD (amino acids 80-82). However, none of these putative functional sites are conserved in the EXT1 protein (12) , and PROSITE predictions suggest that only the RGD site is functional.
Mutations in EXT2
Family 1 is a large EXT family originating from Belgium. This family was used together with family 2 to map the EXT2 gene on chromosome 11 (13) , and to refine the linkage interval afterwards (14) . Lod scores for linkage with the EXT2 linkage interval exceed 3 in this family. SSCP analysis of a genomic PCR fragment of 463 bp amplified with primers A3 and A9 (Table 2 ) and digested with restriction enzyme SAU3AI, revealed an abnormal pattern which was present in all affected patients, but not in the unaffected family members nor in controls (Fig. 6A) . Direct sequencing of this PCR fragment showed heterozygosity for a C→T mutation at nucleotide position 514 of the cDNA (Fig. 6B) . This mutation creates a stop codon TAA at amino acid position 172 (Q172X), leading to a severely truncated EXT2 protein. To confirm the C→T mutation, a modified PCR reaction was developed. Using primers A4 and M1, a 117 bp fragment containing the mutation site was amplified. The mismatched T in primer M1 introduces an NdeI restriction site in the mutated sequence. Digestion with NdeI yields two fragments of 89 and 28 bp if the mutation is present, and a single 117 bp fragment if the mutation is absent. All patients of family 1 showed, in addition to the normal 117 bp amplification product, the fragments associated with the mutation, while unaffected family members and control individuals showed only the normal 117 bp fragment. Therefore, this nonsense mutation is the disease-causing mutation in this family.
SSCP analysis performed so far on patients from family 2 did not show any abberation yet, but further analysis is still in progress.
Family 3 is a multiplex EXT family of Belgian descent which shows linkage to the EXT2 region (maximal lod scores of 2.30 with D11S1393 at zero recombination). SSCP analysis of a 293 bp RT-PCR product from Epstein-Barr virus (EBV)-transformed lymphoblasts amplified by primers 96A and 96E (Table 2) showed an aberrant pattern in this family, not seen in any of the controls. Sequencing revealed the presence of two amplification products, one of expected length and one showing a 94 bp deletion, which interrupts the reading frame and results in a premature stop codon. As both a genomic deletion and aberrant splicing due to a splice site mutation could cause this cDNA deletion, we determined the genomic sequences surrounding these 94 bp. Therefore, P1 clones A1151 and D0494 were subcloned and the 96A-96E fragment was hybridized to the subclones. Sequence analysis of positive clones showed that one intron is located between nucleotides G 1079 and A 1080 , whereas a second intron was found between nucleotides G 1173 and G 1174 . This suggests that the 94 bp cDNA deletion corresponds to a single exon, and that exon skipping due to the presence of a splice site mutation occurs in this family. To prove this hypothesis, intron primers I2 and I4 were designed to amplify the full exon with its boundaries and direct sequencing of this amplification product was performed in two affected patients from family 3. This revealed a g→a mutation at position +1 in the 5′ splice site of the intron following the 94 bp exon (Fig. 7) . Mutation of the completely conserved g to a at position +1 of the 5′ splice site of the intron results in skipping of the 94 bp exon between cDNA nucleotides A 1080 and G 1173 and creates a frame shift after amino acid R 360 , which is followed by 43 novel amino acids and a premature stop codon at amino acid position 404 (Fig. 7) . The mutation therefore yields a truncated EXT2 protein, indicating that this splice site mutation is disease-causing.
DISCUSSION
We report here the isolation of the EXT2 gene through positional cloning of expressed sequences from the EXT2 candidate region. This region was previously defined by us by linkage analysis in large families with hereditary multiple exostoses syndrome, and deletion analysis in the DEFECT 11 microdeletion syndrome. The linkage interval of EXT2 as derived from genetic analysis of key recombinational events in EXT2 families, is a 3 cM region between D11S1355 and D11S1361/D11S554. This whole region is deleted in patients with DEFECT 11 syndrome. However, in one DEFECT 11 patient which showed multiple exostoses, Normal (upper bar) and mutant (lower bar) EXT2 cDNA of family 3, with the corresponding genomic fragment in between. The cDNA deletion of 94 bp (A 1080 -G 1173 ) corresponds to a complete exon which is skipped in the mutant cDNA. This is due to a G→A mutation in the +1 position of the 5′ splice site of the intron immediately following the skipped exon. Due to the frame shift caused by this mutation the mutant protein has 43 novel amino acids after amino acid R 360 (P 361 -L 403 ), followed by a premature stop codon at amino acid position 404. D11S2095, a marker located within the linkage interval between D11S1355 and D11S1361/D11S554, is not deleted. This reduced the EXT2 candidate interval to the region between D11S1355 and D11S2095. Patients with multiple exostoses and a chromosomal translocation in this region that might facilitate the positional cloning of the EXT2 gene, have not yet been reported. Only a small deletion of D11S903 has been described in a family with EXT2, but DNA from this family was not made available to us. Therefore, a contig of YAC and P1 clones of the complete candidate region between D11S1355 and D11S2095 was constructed, and expressed sequences were isolated from this region. One clone showed homology at the amino acid level with EXT1 and was therefore pursued. The compiled sequence assembled from cDNA clones obtained by cDNA selection, cDNA screening and PCR extensions, contains 3320 bp. Throughout the cDNA there exists homology with the EXT1 gene on chromosome 8q24. EXT1 and EXT2 are similar genes with a large size of >100 kb, encoding homologous proteins of 700-750 amino acids that are ubiquitously expressed. This suggests that EXT1 and EXT2 form a family of genes that are possibly derived from one ancestor gene. It will be interesting to see whether or not the EXT3 gene on chromosome 19 will be also homologous to EXT1 and EXT2.
The open reading frame of EXT2 contains 2154 bp encoding 718 amino acids, whereas EXT1 has 754 amino acids. Especially in the 3′ region of both genes, homology at the protein level is high, but conserved functional domains could not be found in this region. A3  5′-CACCCTCTTCTCCATTGTCCTCC-3′  81→103  A4  5′-CTACTACACTGATGACATCAACCG-3′  423→446  A9  5′-GATCCCACCTAGAGAGCTGGGCC-3′  522→544  M1  5′-CCACCTAGAGAGCTGGGCCATCGCAT  515→540  96A  5′-GATTACCCACAGGTGCTACAGG-3′  919→940  96E  5′-CAGGGTGGCCAGGGCAATGGC-3′  1213→1233  I2  5′-GGGATGTGGGGCTGAAGGAGG-3′  INTRON  I4 5′-GGCCACCATTTCGGTACCACCC-3′ INTRON Although the genomic structure and intron-exon boundaries of the EXT2 gene are not yet clear, it must be a large gene as it hybridizes to P1 clones D0494 and D0694 that are >100 kb apart. The 3′ end of the EXT2 gene is located near D11S2095, an anonymous marker that forms the boundary of the candidate region of the putative FPP gene which is responsible for Foramina Parietale Permagna in the DEFECT 11 syndrome. It is therefore likely that the FPP gene is located between the EXT2 gene and D11S1355 which forms the telomeric boundary of the minimal deleted region in patients with FPP due to the DEFECT 11 syndrome (24). However, theoretically it is also possible that FPP is caused by mutations in the EXT 2 gene.
The nature of the physiologic function of the EXT2 gene remains elusive, although it is likely that the EXT1 and EXT2 genes have a similar function in view of their structural homology and the similarity of the disease phenotype. Computer analysis of the many putative EXT2 protein sites predicts that only the RGD cell attachment site is functional. RGD sequences (36) bind to members of the integrin family and are present on >100 proteins, including bone matrix RGD proteins such as fibronectin, vitronectin, type I collagen, osteopontin, bone sialoprotein and thrombospondin (37) . These matrix proteins interact with both osteoblastic (37) and osteoclastic (38) bone cells. The integrins which are cell adhesion molecules, thereby connect the extracellular matrix with the intracellular cytoskeleton. Some cell adhesion molecules have RGD sites themselves, and are involved in cell-cell attachment. The presence of an RGD site and a short hydrophobic region predicted to be a transmembrane region (between amino acids 24 and 43), might be compatible with the EXT2 gene product being a cell surface molecule involved in cell-cell interaction. Some proteins involved in cell adhesion and cell signaling such as DCC (deleted in colon carcinoma), APC (adenomatous polyposis coli) and NF2 (neurofibromatosis type 2) are tumor-suppressor genes (39) (40) (41) . Also EXT2 and EXT1 might be tumor suppressor genes. This hypothesis is based upon several arguments. First, LOH of the EXT1 and EXT2 region has been documented in chondrosarcoma and osteosarcoma occurring both in sporadic form or as a neoplastic degeneration of an enchondroma in EXT (17, 18) . It is, of course, not excluded that the LOH regions include additional genes that have a tumor-suppressor function. Second, the three mutations that have been reported in EXT1 and EXT2 are loss-of-function mutations, e.g. nonsense mutations or frameshift mutations leading to a premature stop codon. This is corroborated by the presence of deletions of the EXT1 and EXT2 gene respectively in the Langer-Giedion syndrome and the DEFECT 11 syndrome (Fig. 8) . Third, apart from these constitutional null alleles, somatic chromosomal rearrangements in the EXT1 region on chromosome 8q24 have also been found in sporadic osteocartilaginous exostoses (19) .
Formal proof that EXT1 and EXT2 are tumor suppressor genes will await the identification of somatic intragenic mutations in chondrosarcoma or osteosarcoma. Although the classical paradigm of tumor suppressor genes is homozygous loss-of-function by germline and/or somatic inactivation, loss of only one copy of a number of tumor suppressor genes leads to a clear phenotype. In some conditions such as APC and NF1/NF2, the hemizygous state of the tumor suppressor gene leads to benign tumors such as adenoma and neurofibroma, respectively. Additional loss of the second allele, loss of other tumor suppressor genes and activation of oncogenes subsequently leads to malignant degeneration to colorectal adenocarcinoma and neurofibrosarcoma, respectively. In analogy, constitutional loss-of-function mutations in the EXT1 or EXT2 gene might lead to enchondromata (multiple exostoses), whereas further loss of additional tumor suppressor genes and activation of oncogenes might lead to sarcomatous degeneration of the enchondromata to chondrosarcoma or osteosarcoma. This putative oncogenetic model is reminiscent of that of colorectal tumorigenesis as put forward by Vogelstein and Kinzler (42) . Consequently, EXT1 and EXT2 might be paradigms to study the oncogenesis of chondrosarcoma and osteosarcoma in general.
MATERIALS AND METHODS
EXT2 families
EXT2 mutation analysis was performed in three large multiplex families with multiple exostoses linked to the EXT2 region. Two of these families, family 1 of Belgian descent and family 2 of Dutch origin, have been reported before (13, 14) . From family 3, also originating from Belgium, DNA is available from 19 individuals, eight of them being affected with EXT. For several patients from these three families, RNA was also available.
Molecular analysis of a DEFECT 11 patient
The patient has WAGR syndrome with Wilms' tumor, aniridia, genital abnormalities and mental retardation. Clinical aspects of this patient have been described previously (30) . The patient also shows multiple exostoses, and retrospectively was recognized by us to have the DEFECT 11 syndrome with multiple exostoses (EXT), enlarged foramina parietale (FPP) and mental retardation. Chromosomal studies revealed an interstitial deletion 11p11.2-p14.2. Molecular analysis was performed on DNA of the patient, his mother and his sister, but no DNA from the father was available. Chromosome 11 markers D11S1361, D11S2095, D11S903, D11S1355, D11S935, D11S914 and D11S915 were analyzed by PCR. 
Southern and Northern blotting
Southern blotting to Hybond N + membranes (Amersham) was performed according to the recommendations of the manufacturers. Probes were labeled using the T7 QuickPrime Kit (Pharmacia). Hybridization and washing were performed using standard laboratory protocols. Hybridization of EXT2 cDNA yf69b06 to a commercially available Northern blot from Clontech was performed as recommended by the manufacturers.
YAC and P1 library screening
The chromosome 11-specific YAC library was screened extensively by PCR with markers D11S1355, D11S578 and D11S903 using primers and annealing temperatures as described in GDB. The ICRF (43) and CEPH YAC libraries, a chromosome 11-specific cosmid library (ICRF) and a P1 library (ICRF) were screened by hybridization respectively, with an STS from D11S1355 and with YAC 923B11. The names of the ICRF P1 clones are abbreviated in this paper and should be preceded by the prefix ICRFP700 in order to obtain the full clone name. Cosmid ICRFc107E07123 is abbreviated to E07123.
DNA preparation
Genomic DNA from EXT2 patients, the DEFECT11 patient, family members and controls was extracted from leukocytes by standard techniques. YAC DNA in solution was prepared according to standard laboratory protocols. To isolate the artificial chromosome from the yeast chromosomes, YAC 923B11 agarose plugs were prepared for loading on a preparative pulsed field gel. YAC 923B11 was grown in AHC medium, and 80 µl 0.5% agarose plugs containing 1 × 10 8 cells were prepared. Plugs were incubated for 2 h at 37_C in CPE (40 mM citric acid, 120 mM Na 2 HPO 4 and 20 mM EDTA, pH 8.0) containing 0.5 mg/ml zymolyase. Plugs were washed in TE -4 , incubated for 48 h at 50_C in 0.5 M EDTA (pH 8.0) containing 1 mg/ml proteinase K and 1% N-lauroylsarcosine, washed again and stored in 0.5 M EDTA (pH 8.0) at 4_C. YAC 923B11 DNA was isolated by preparative pulsed field gel electrophoresis in 1% agarose gels in 0.5× TBE using a CHEF-DR III apparatus (BIO-RAD) at 6 V/cm for 38 h and an increasing switch time from 80 to 147 s. DNA from P1 clones, cosmids and plasmids were all prepared using the Qiaprep Spin Kits (Qiagen).
FISH analysis
FISH and immunocytochemical detection of P1 and cosmid clones on mitotic chromosome spreads obtained from peripheral blood lymphocytes, were carried out as described previously (44) , with R-banding according to Cherif et al. (45) . Interphase FISH mapping was performed using the alkaline-borate treatment (46) at 1 mM borate concentration. For fiber FISH the procedure of Parra and Windle (47) was followed. An Olympus BX40 was used for fluorescence microscopy and the results were photographed on a PSI-probemaster 3 station.
cDNA selection
Protocols used for cDNA selection were as described (48) with modifications. Pooled P1 DNA (1 µg) was biotinylated by nick translation. This DNA was hybridized to cDNA obtained from human liver tissue that had previously been randomly primed and ligated to adaptors (B. Korn, unpublished information). Human cot-1 DNA and P1 vector DNA were added as competitors during this hybridization. Hybridization was performed at 65_C for 16 h. Heteroduplexes of genomic templates and cDNA were immobilized using Streptavidin-coated magnetic beads (Dynal). After washing of the magnetic beads with 0.1× SSC, the cDNA fragments are eluted by denaturation of the heteroduplexes at 95_C for 5 min. Eluted fragments were selected according to size using Chromaspin400 columns (Clontech), and amplified by PCR using the SK primer (5′-GCC GCT CTA GAA CTA GTG GAT C-3′). A second round of cDNA selection was performed using the SK-U primer (5′-CUA CUA CUA CUA GCC GCT CTA GAA CTA GTG GAT C-3′). Finally, amplified cDNAs were cloned using the CloneAmp System from BRL, and transformed into Escherichia coli DH5α cells.
5′ RACE experiments
5′ RACE experiments were performed using the Human Leukocyte Marathon-Ready cDNA kit (Clontech) according to the recommendations of the manufacturer. Thirty PCR cycles of 30 s at 94_C, 30 s at 63_C and 4 min at 68_C were performed using adaptor primer AP1 and primer L2 (5′-CCATggACACTTCATTCgTCCACTCAgACTC-3′) located in EXT2 cDNA clone yf69bo6 (Fig. 1) . A second RACE experiment was performed with a nested PCR using adaptor primer AP2 and primer C2 (5′-ggtgattcgtacctcgatcccacc-3′). The amplification products were subcloned into pUC18 vector with the Sureclone Ligation Kit (Pharmacia), and transformed into competent E.coli DH5α cells. The size of the inserts of the clones was estimated by PCR and gel electrophoresis, and the 5′ RACE products were sequenced.
RNA isolation and RT-PCR
Total RNA was isolated from EBV-transformed cell lines with trizol according to the manufacturer's instructions (Gibco BRL). For the synthesis of cDNA, 5 µg of total RNA was reverse transcribed with an Oligo(dT) [12] [13] [14] [15] [16] [17] [18] primer using the SuperScript Preamplification System (Gibco BRL). The cDNA products were directly used as templates for PCR amplification.
SSCP sequencing
SSCP analysis of PCR (DNA) and RT-PCR (cDNA) fragments was performed according to standard protocols using HydroLink MDE Gel (J. T. Baker). Sequence analysis, based on the dideoxy method, was performed by dye terminator sequencing with Taq polymerase on an ABI-373 sequencer (Perkin-Elmer). For direct sequencing, PCR or RT-PCR fragments were purified from agarose gels with Spinbind columns (FMC). Sequencing reactions on PCR or RT-PCR products were performed with one of the amplification primers, whereas plasmid inserts were sequenced with vector primers.
Database searches and computer analysis
Homology searches were performed with different BLAST programs, BLASTN, BLASTX, TBLASTN and TBLASTX (35) . The PROSITE and Tmpred packages were used for protein analysis by direct access to the servers via the worldwide web (http://www.ebi.ac.uk/searches/prosite.html).
